science wire

Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable   Patients had a 65% chance of being relapse-free o

Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer Comparison of Jakavi (ruxolitinib) vs.

Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%) About two-thirds of patients

FDA approves Roche's Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery Avastin is now approved for ten distinct uses across six different types of cancer in the United States Roche today announced that the US Food and Drug Administration (FDA) has approved Avastin (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection.

Approval based on phase III MURANO study showing Venclexta plus Rituxan reduced risk of disease progression or death by 81% compared to bendamustine plus Rituxan Roche , announced today that the Unit

Novartis announces JCO publication of Lutathera NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs Patients repor

Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Hemlibra (emicizumab-kxwh) for adults and children with haemophilia A without factor VIII inhibitors.

Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell

Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy (

Phase III IMpower130 study showed Roche's Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to

Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) These improvements were reported early by Entresto patients, with a median follow-up time of 32 days 21&

Scientists at the Universities of Birmingham and Nottingham have joined their counterparts at Brazil's National Center for Research in Energy and Materials (CNPEM) to develop the next generation of drugs to tackle two of the planet's biggest killers, cardiovascular disease and cancer.

In a subset of patients in the HAVEN 3 study who previously received factor VIII prophylaxis, the standard of care, Hemlibra reduced bleeds by 68 percent compared to their prior therapy Phase III HAV

Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States   Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-related p

Results from the Kisqali MONALEESA clinical trial program, the largest industrysponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be pre

A survival advantage for the Tecentriq and Avastin combination regimen was observed in all pre-specified exploratory patient subgroups analysed, including people with EGFR and ALK mutations, liver me

Human cells are enclosed by membranes and are in osmotic equilibrium with their environment. If the concentration of solute molecules (osmolarity) in the fluid surrounding the cells decreases, cells start to swell; in extreme cases, this can result in the cells bursting.

Data include results from HAVEN 3 study in people with haemophilia A without factor VIII inhibitors and HAVEN 4 study in people with haemophilia A with or without factor VIII inhibitors Ongoing Hemli

New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)   In a landmark controlled

Farnesoid X receptor- is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo Abstract: Hepatitis B virus (HBV) infection and bile acid (BA) metabolism are in

Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer Roche today announc

Rheumatoid arthritis (RA) patients of South Asian origin now have extra help in living with a painful and incurable condition - thanks to a new educational video that encourages them to understand when and why they need to move from standard treatment to treatment with a biologic.

FDA grants priority review to Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer Roche today announced that the US Fo

Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week 48 Pr

Tafinlar + Mekinist is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection  

Significant political and economic uncertainty characterises the Brexit process one year after the UK triggered Article 50, reveals a new report by the academic group, The UK in a Changing Europe, which includes University of Birmingham Researchers.

In the large phase III APHINITY study, the combination of Perjeta, Herceptin and chemotherapy significantly reduced the risk of invasive breast cancer recurrence or death by 19% compared to Herceptin

Company to invest more than USD 100 million to advance research and development of new antimalarials over the next five years   Commitment includes expanding access to pediatric antimalarials and imp

Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures The LIBERTY trial studie

Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine to show superior efficacy compared to prior fact

Scientists at the University of Birmingham have been awarded nearly £3 million from Cancer Research UK to investigate cancers that are resistant to treatment.

Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes Heart failure (HF) patients with reduced

A study by the University of Birmingham has revealed a treatment gap in patients suffering from a heart condition that causes an irregular or abnormally fast heartbeat. Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major global public health problem. It is associated with a five-fold increase in risk of stroke.

Sandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcare Publication, which coincides with World Healt

Novartis announces JAMA Cardiology publication of data showing Entresto improves physical and social activity in HFrEF patients versus enalapril Post-hoc analysis of PARADIGM-HF published in JAMA Car